About ScreeningForCancer.org: Archival Provenance & Editorial Charter
ScreeningForCancer.org is an independent clinical epidemiology and risk-literacy publication dedicated to comparing multi-society cancer screening guidelines (USPSTF, ACS, NCCN, UK NHS, and East Asian national programs) using denominator-stabilized 1,000-person outcome tables. We accept zero advertising, pharmaceutical sponsorship, or commercial lab referral fees.
1. Historical Provenance of the Domain (2015 USPSTF vs. ACS Debate)
During the landmark 2015-2016 public comment and guideline revision cycle - when the U.S. Preventive Services Task Force (USPSTF) released its draft breast cancer screening recommendations alongside the American Cancer Society's updated JAMA guideline - screeningforcancer.org (together with its sister portal screeningforbreastcancer.org) was referenced in clinical literature, including by Harvard Medical School's Harvard Health Publishing, as a public reference point for understanding why guideline panels arrive at different starting ages.
After the original public comment microsite went dormant, our editorial desk rebuilt ScreeningForCancer.org to preserve that historical link equity and expand its mission into a permanent, multi-organ, trilingual (English, Spanish, and Simplified Chinese) clinical concordance reference.
2. Statement of Non-Affiliation & Editorial Independence
ScreeningForCancer.org is an independent medical reference publication and is not affiliated with, endorsed by, or operated by the U.S. Preventive Services Task Force (USPSTF), the Agency for Healthcare Research and Quality (AHRQ), the U.S. Department of Health and Human Services (HHS), or the American Cancer Society (ACS). Official federal task force documents are published at uspreventiveservicestaskforce.org.
Our editorial funding is 100% independent. We do not accept sponsorships from liquid biopsy manufacturers, commercial full-body MRI chains, pharmaceutical companies, or hospital networks.
3. Primary Clinical Literature & Modeling Sources
- USPSTF Final Recommendations & Evidence Syntheses: Breast (2024), Colorectal (2021), Lung (2021), Cervical (2018/2025 draft), Prostate (2018), Ovarian (2018), Pancreatic (2019), Thyroid (2017).
- CISNET (Cancer Intervention and Surveillance Modeling Network): National Cancer Institute microsimulation models quantifying life-years gained, false-positive recalls, and overdiagnosis per 1,000 screenees.
- Harding Center for Risk Literacy & Cochrane Systematic Reviews: Absolute risk Fact Box methodology developed by Prof. Gerd Gigerenzer and colleagues.
Frequently Asked Clinical Questions
Plain-language answers grounded in USPSTF, ACS, and 1,000-person cohort data.
Can clinicians print these 1,000-person outcome tables for patient shared decision-making?
Yes. Every page on ScreeningForCancer.org includes a dedicated print stylesheet (@media print) that strips navigation chrome and formats the multi-society concordance matrices and 1,000-person outcome scales cleanly onto standard Letter or A4 pages for clinic consultations.